KR102362960B1 - Functional composition for anti-inflammatory and skin improvement comprising caviar enzyme-treated powder extract as an active ingredient. - Google Patents
Functional composition for anti-inflammatory and skin improvement comprising caviar enzyme-treated powder extract as an active ingredient. Download PDFInfo
- Publication number
- KR102362960B1 KR102362960B1 KR1020210092608A KR20210092608A KR102362960B1 KR 102362960 B1 KR102362960 B1 KR 102362960B1 KR 1020210092608 A KR1020210092608 A KR 1020210092608A KR 20210092608 A KR20210092608 A KR 20210092608A KR 102362960 B1 KR102362960 B1 KR 102362960B1
- Authority
- KR
- South Korea
- Prior art keywords
- caviar
- enzyme
- inflammatory
- powder
- treated
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 캐비아 효소처리 분말 추출물을 유효성분으로 포함하는 항염증 및 피부 개선용 기능성 조성물에 관한 것이다. 더욱 상세하게는 캐비아를 효소처리하여 분말화한 추출물을 제공함으로서 안전하게 사용이 가능한 항염증 및 피부 개선용 기능성 식품, 건강기능식품 조성물을 제공한다.The present invention relates to a functional composition for anti-inflammatory and skin improvement comprising a caviar enzyme-treated powder extract as an active ingredient. More specifically, it provides an anti-inflammatory and skin-improving functional food and health functional food composition that can be safely used by providing a powdered extract by enzymatic treatment of caviar.
면역은 생체의 내부환경이 꽃가루, 음식물, 약, 미생물, 바이러스와 같은 항원에 대해 방어하는 현상으로 태어날 때부터 존재하는 선천면역과 후천적으로 획득하는 후천면역이 있다. 선천면역은 항원에대해 비특이적으로 반응하며 피부, 점액조직, 위산, 대식세포 등이 담당한다. 후천면역은 항원에 대해 특이적으로 반응하며 체액성 면역, 세포성 면역으로 나뉜다. 면역 반응의 대표적인 결과로 염증 반응이 있다. 염증은 외상, 화상과 같은 조직의 손상 또는 세균 감염, 특정 항원에 대한 반응이며 부종, 발열, 통증을 일으키는 증상이다. Immunity is a phenomenon in which the internal environment of a living body defends against antigens such as pollen, food, drugs, microorganisms, and viruses. Innate immunity responds non-specifically to antigens, and skin, mucous tissue, gastric acid, and macrophages are responsible for it. Acquired immunity responds specifically to antigens and is divided into humoral immunity and cellular immunity. A typical result of an immune response is an inflammatory response. Inflammation is trauma, tissue damage such as burns, bacterial infection, or a reaction to a specific antigen, and is a symptom that causes swelling, fever, and pain.
이러한 염증은 조직의 손상 부위나 감염 부위가 작거나 일시적이면 급성염증으로 끝나는 반면, 만성적 감염 상태나 염증 부위가 크면 만성염증이 진행된다. 염증관련 산업은 식약처 <2018 식품 등의 생산실적 통계>에 따르면, 2018년 면역기능 건강기능식품은 1조 2588억원의 매출액으로 가장 높은 비중을 차지하였으며, 염증에 의해 유발될 수 있는 각종 질병과 관련한 기능성식품의 수요가 끊임없이 증가하는 추세이다.Such inflammation ends with acute inflammation when the tissue damage or infection site is small or temporary, whereas chronic inflammation progresses when the chronic infection state or inflammation site is large. According to the Ministry of Food and Drug Safety's <2018 Food Production Performance Statistics>, the immune function health functional food accounted for the highest proportion in sales of 1.25 trillion won in 2018, and various diseases that can be caused by inflammation and The demand for related functional foods is constantly increasing.
또한 이너뷰티(Inner Beauty)는 먹는 화장품을 말하며, 식습관과 생활습관을 바꾸어 피부 속 건강을 향상시키고 피부 자체를 좋아지게 하는 것을 말한다. 인더스트리 애널리스트 보고서에서 먹는 화장품 또는 미용식품을 의미하는 '뉴트리코스메틱스(Nutricosmetics)'의 글로벌 시장 규모가 2013년에는 41억 달러였으나 2020년에는 74억달러 규모로 성장할 것으로 예측한 만큼 그 가치가 무궁무진하다. 특히 국내 이너뷰티 시장은 2011년부터 5년간 연평균 68.2%의 급성장을 이뤘으며 뷰티 업계의 주요 시장으로 자리매김하고 있다. 그러나 생산 제품의 주된 원료로는 콜라겐, 히알루론산, 비타민 등 기존 화장품과 연결된 한정적 원료이다.Also, inner beauty refers to eating cosmetics, and it refers to improving the health of the skin and improving the skin itself by changing eating habits and lifestyle. According to the Industry Analyst Report, the global market for 'Nutricosmetics', which refers to cosmetics or beauty foods to eat, was $4.1 billion in 2013, but is expected to grow to $7.4 billion in 2020, so its value is limitless. In particular, the domestic inner beauty market has grown rapidly at an average annual rate of 68.2% for five years from 2011, and is establishing itself as a major market in the beauty industry. However, the main raw materials for production products are limited raw materials linked to existing cosmetics such as collagen, hyaluronic acid, and vitamins.
한편, 철갑상어(Acipenser sinensis)는 조기어강 철갑상어목 철갑상어과에 속하는 어류의 일종으로 비늘이 없는 유선형 몸체를 가지고 있으며 몸길이가 2~5m 정도까지 달하는 대형 어종이다. 철갑상어의 알은 캐비아라고 하며 벨루가, 오세트라, 세브루가 등 철갑상어의 종류에 따라 구분이 된다. On the other hand, the sturgeon ( Acipenser sinensis ) is a kind of fish belonging to the sturgeon family, and it is a large fish species with a streamlined body without scales and a body length of 2 to 5 m. Sturgeon eggs are called caviar and are classified according to the type of sturgeon, such as beluga, osetra, and sevruga.
캐비아는 지방이 적고 비타민과 단백질이 많아 고급 요리 재료로 쓰인다. 수술 후 환자들의 회복식으로 기름만을 뽑아 마시기도 했고, 야채를 많이 섭취하지 못하는 추운 지방에서 결핍되기 시운 비타민 섭취 대용 역할을 하기도 했다. 또한, 노화 방지에도 상당히 효과가 있어 캐비아를 이용한 화장품도 다수 등장했다.Caviar is low in fat and high in vitamins and protein, so it is used as an ingredient in high-end cuisine. After surgery, patients only drank oil as a recovery meal, and they acted as a substitute for vitamin intake, which was lacking in cold regions where vegetables were not consumed. In addition, it is very effective in anti-aging, so many cosmetics using caviar have appeared.
본 발명은 식품 또는 화장품 원료로 사용되는 캐비아를 초임계추출 및 효소처리를 통해 어취를 감소시키고 지질이 제거한 캐비아 재료를 이용하여 항염증 및 피부 개선 효과를 나타내는 기능성 조성물로 활용하고자 한다. The present invention intends to utilize caviar used as a food or cosmetic raw material as a functional composition showing anti-inflammatory and skin improvement effects by reducing fish odor through supercritical extraction and enzyme treatment and using caviar material from which lipids have been removed.
식품 또는 화장품 원료로 사용되는 캐비아를 초임계추출을 통해 어취를 감소시키고 지질이 제거한 캐비아 단백질을 효소 처리함으로서 항염증 및 피부 개선 효과를 나타내는 조성물을 제공하는 것을 목적으로 한다.An object of the present invention is to provide a composition showing anti-inflammatory and skin improvement effects by reducing fish odor through supercritical extraction of caviar used as a food or cosmetic raw material and enzymatically treating caviar protein from which lipids have been removed.
상기 목적을 달성하기 위하여, 본 발명은 캐비아 효소처리 분말 추출물을 유효성분으로 포함하는 항염증 및 피부 개선용 기능성 조성물을 제공한다.In order to achieve the above object, the present invention provides a functional composition for anti-inflammatory and skin improvement comprising a caviar enzyme-treated powder extract as an active ingredient.
상기 캐비아는 초임계추출 방법으로부터 가용한 추출물이고 초임계추출 압력은 400 bar, 온도 40℃, 유속 60 ml/min, 추출시간 300분의 조건으로 이루어진다. The caviar is an extract available from the supercritical extraction method, and the supercritical extraction pressure is 400 bar, a temperature of 40° C., a flow rate of 60 ml/min, and an extraction time of 300 minutes.
상기 캐비아 효소처리 분말 추출물은 캐비아 탈지분말의 10배수의 증류수를 첨가한 뒤, 효소 Prozyme 1000L와 Protamex를 동시에 처리하거나, 효소 Prozyme 1000L로 1차 처리하고 효소 Protamex로 2차 처리하여 얻어진 항염증 및 피부 개선용 기능성 조성물을 제공한다. The caviar enzyme-treated powder extract is anti-inflammatory and skin obtained by adding
상기 조성물에는 캐비아 효소처리 분말 추출물이 0.01 내지 10 g/day의 양으로 포함하여 제조될 수 있고, 또는 캐비아 효소처리 분말 추출물이 0.01내지 100중량%의 양으로 포함하는 항염증 및 피부 개선용 기능성 조성물을 제공한다.In the composition, the caviar enzyme-treated powder extract may be prepared in an amount of 0.01 to 10 g/day, or the caviar enzyme-treated powder extract in an amount of 0.01 to 100 wt% Anti-inflammatory and skin improvement functional composition provides
본 발명의 캐비아 효소처리 분말 추출물을 포함하는 항염증 및 피부 개선 조성물은 이산화탄소로 초임계추출하며, 식품으로 사용되는 캐비아에 식용 가능한 효소로 분해하여 안전하며, 복용이 용이하고, 장기간 보관이 가능하며, 항염증 및 피부 개선 효과가 우수하다.The anti-inflammatory and skin improvement composition comprising the caviar enzyme-treated powder extract of the present invention is supercritically extracted with carbon dioxide, and it is safe by decomposing it with an edible enzyme in caviar used as food, easy to take, and can be stored for a long time. , has excellent anti-inflammatory and skin improvement effects.
도 1은 캐비아 효소처리 분말 제조법의 모식도를 나타낸다.
도 2은 RAW264.7 세포에서 캐비아 효소처리 분말 및 열수추출분말의 세포독성 결과
도 3은 RAW264.7 세포에서 조건 별 열수추출분말 및 효소처리 분말의 IL-6 감소 효과를 나타낸다.
도 4는 RAW264.7 세포에서 조건 별 열수추출분말 및 효소처리 분말의 TNF-α 감소 효과를 나타낸다.
도 5는 Hs68 세포에서 조건 별 열수추출분말 및 효소처리 분말의 MMP-1 발현 감소 효과를 나타낸다.
도 6은 Hs68세포에서 조건 별 열수추출 분말과 효소처리 분말의 COL1A 증가 효과를 나타낸다.
도 7은 Hs68세포에서 조건 별 열수추출분말과 효소처리 분말의 Fibrillin 발현 증가 효과를 나타낸다.
도 8은 본 발명으로부터 완성된 캐비아 효소처리 분말 조성물을 나타낸다.1 shows a schematic diagram of a caviar enzyme-treated powder manufacturing method.
2 is a cytotoxicity result of caviar enzyme-treated powder and hot water extract powder in RAW264.7 cells.
3 shows the IL-6 reduction effect of hot water extract powder and enzyme-treated powder for each condition in RAW264.7 cells.
4 shows the TNF-α reduction effect of hot water extract powder and enzyme-treated powder for each condition in RAW264.7 cells.
5 shows the effect of reducing MMP-1 expression of hot water extract powder and enzyme-treated powder for each condition in Hs68 cells.
6 shows the effect of increasing COL1A of hot water extract powder and enzyme-treated powder for each condition in Hs68 cells.
7 shows the effect of increasing the fibrillin expression of hot water extract powder and enzyme-treated powder for each condition in Hs68 cells.
8 shows the caviar enzyme-treated powder composition completed from the present invention.
본 발명은 캐비아 효소처리 분말 추출물을 유효성분으로 포함하는 항염증 및 피부 개선용 조성물에 관한 것이다. 이하 구체적인 실시예를 들어 상세히 설명한다.The present invention relates to a composition for anti-inflammatory and skin improvement comprising a caviar enzyme-treated powder extract as an active ingredient. Hereinafter, it will be described in detail with reference to specific examples.
I. 캐비아 효소처리 분말의 제조 및 조건별 수율비교I. Preparation of caviar enzyme-treated powder and comparison of yields by condition
1. 캐비아 효소처리 분말 제조1. Preparation of caviar enzyme-treated powder
1) 동결건조1) Freeze drying
본 발명의 캐비아 효소처리 분말 제조법은 캐비아 원물 3,000g을 동결건조하여 분말화한다. 동결건조 분말화하면 수분이 증발되어 1,200g으로 원물대비 수율 40%를 나타낸다. In the caviar enzyme-treated powder manufacturing method of the present invention, 3,000 g of raw caviar is lyophilized and powdered. When freeze-dried powder is evaporated, the yield is 40% compared to the raw material at 1,200 g.
2) 초임계추출2) Supercritical extraction
캐비아 동결건조분말 1,200g을 초임계 추출하여 캐비아 탈지분말을 얻는다. 초임계 추출은 압력 400 bar, 온도 40℃, 유속 60 ml/min, 추출시간 300분의 조건으로 이루어진다. 초임계추출을 통해 동결건조분말 대비 80%의 수율로 960g을 얻을 수 있다. 1,200 g of freeze-dried caviar powder is supercritically extracted to obtain caviar skim powder. Supercritical extraction is performed under the conditions of a pressure of 400 bar, a temperature of 40 °C, a flow rate of 60 ml/min, and an extraction time of 300 minutes. Through supercritical extraction, 960 g can be obtained with a yield of 80% compared to the freeze-dried powder.
본 발명에서 사용된 초임계유체추출법(Supercritical Fluid Extraction, SFE)은 임계온도 및 경계압력을 초과하는 상태의 유체인 초임계 유체를 이용한 추출법으로 일반적으로 불활성, 무미, 무취, 무해인 이산화탄소를 이용한다. 또한, 상압 부근에서는 유체가 기화하기 때문에 추출 성분만 얻을 수 있는 장점이 있어 의약품이나 식품에도 사용된다. 초임계추출의 응용 예시로 커피의 탈 카페인, 어류에서 EPA 추출, 식품의 저지방 및 저콜레스테롤화 처리 등이 있다.The supercritical fluid extraction (SFE) used in the present invention is an extraction method using a supercritical fluid, which is a fluid in a state exceeding the critical temperature and boundary pressure, and generally uses inert, tasteless, odorless, harmless carbon dioxide. In addition, since the fluid vaporizes in the vicinity of atmospheric pressure, it has the advantage of obtaining only an extractable component, so it is used in pharmaceuticals and food. Examples of applications of supercritical extraction include decaffeination of coffee, EPA extraction from fish, and low-fat and low-cholesterolization treatment of food.
3) 효소처리3) Enzyme treatment
캐비아 탈지분말의 10배수의 증류수를 첨가한 후, 효소처리를 실시한다. 효소는 Prozyme 1000L와 Protamex를 각각 원물 중량 대비 1%, 2.5%, 5%씩 처리하였다. 증류수와 효소처리된 캐비아 탈지분말은 50℃에서 4시간 가열 후, 90℃에서 30분간 효소 활성을 상실시킨다.After adding distilled
본 발명에 사용된 효소로서 Prozyme 1000L은 Bacillus licheniformis와 Bacillus amyloliquefaciens의 배양물에서 얻어진 endo형 프로테이즈이다. 단백질을 빠르게 분해하여 수용성 펩타이드를 생성하기 때문에 단백질의 1차 분해용으로 적합하다. 또한 Protamex는 Bacillus 속의 배양물에서 얻어진 exo형 프로테이즈이다. endo형 프로테이즈에 의해 1차 분해된 단백질을 exo형 프로테이즈인 Protamex가 2차 분해를 하게 된다.As the enzyme used in the present invention, Prozyme 1000L is an endo-type protease obtained from cultures of Bacillus licheniformis and Bacillus amyloliquefaciens . Since it rapidly decomposes proteins to produce water-soluble peptides, it is suitable for the primary decomposition of proteins. Also, Protamex is an exo-type protease obtained from a culture of the genus Bacillus . Proteins firstly degraded by endo-type proteases are secondarily degraded by exo-type proteases, Protamex.
4) 여과 농축 및 동결건조4) Filtration concentration and freeze-drying
캐비아 효소처리액을 여과 후 여과액을 15brix까지 농축하고 농축된 15brix 농축액을 동결건조하여 캐비아 효소처리 분말 기능성 조성물을 제조하였다.After filtering the caviar enzyme-treated solution, the filtrate was concentrated to 15brix, and the concentrated 15brix concentrated solution was freeze-dried to prepare a caviar enzyme-treated powder functional composition.
2. 캐비아 효소처리 분말 조성물의 효소처리 조건별 수율비교2. Comparison of Yield of Caviar Enzyme-treated Powder Composition by Enzyme Treatment Conditions
표 1은 조성물제조 조건별 캐비아 추출 수율을 나타낸다. 표의 설명에서 1차 효소처리는 탈지분말 그대로 효소처리한 결과를 나타내고, 2차 효소처리는 탈지분말 분쇄 (140mesh) 후, 효소처리한 결과를 나타낸다. 3차 효소처리는 탈지분말 그대로, 효소 투입량을 1%에서 5% 또는 10%로 증량하여 효소처리한 결과를 나타낸다. Table 1 shows the caviar extraction yield for each composition preparation condition. In the description of the table, the primary enzyme treatment shows the results of enzyme treatment as it is, and the secondary enzyme treatment shows the results of enzyme treatment after pulverization of the skim powder (140mesh). The tertiary enzyme treatment shows the result of enzyme treatment by increasing the amount of enzyme input from 1% to 5% or 10% as it is with skim powder.
또한 샘플명에서 효소처리 x는 효소를 투입하지 않고 효소 처리군과 같은 조건으로 가열한 결과를 나타내며, 팽윤 + 효소처리는 증류수에 1시간 팽윤하여 조직을 연하게 한 뒤, 효소처리한 결과를 나타낸다. In addition, in the sample name, enzyme treatment x indicates the result of heating under the same conditions as in the enzyme treatment group without adding enzyme, and swelling + enzyme treatment indicates the result of swelling in distilled water for 1 hour to soften the tissue, and then enzyme treatment .
결과를 살펴보면, 탈지분말 분쇄 시(2차 효소처리) 수율은 증가했으나, 캐비아 원재료 단가를 감안하여 실제 분쇄 공정에서 손실 때문에 적합하지 않는 것으로 판단된다.(1 내지 5번) 분쇄 공정을 제외하고 효소 투입량을 증가시킨 결과(3차 효소처리), 수율이 대폭 증가하였고(6 내지 11번), 단일 효소를 사용하기보다는 혼합하여 효소를 사용하였을 때 수율 높은 것을 알 수 있었다.(8-11번) Looking at the results, the yield increased during pulverization of skim powder (secondary enzyme treatment), but it is judged that it is not suitable due to loss in the actual pulverization process in consideration of the unit cost of caviar raw material. (No. 1 to 5) Except for pulverization process, enzyme As a result of increasing the input amount (tertiary enzyme treatment), the yield was significantly increased (No. 6 to 11), and it was found that the yield was high when mixed enzymes were used rather than single enzymes (No. 8-11).
또한 조직 연화를 목적으로 팽윤 후, 효소처리한 결과가 팽윤 처리하기 전보다 수율이 높지 않은 것을 알 수 있다.(10-11번) 팽윤하지 않은 8-9번 결과 중 9번 조건이 수율 21%로 가장 높았으나 여과 과정에서 여과가 잘 되지 않아 여과 시간이 오래 걸리고, 필터 사용량이 많은 문제를 보임에 따라, 대량 생산시 8번 조건이 가장 적합할 것으로 판단된다. 즉, 대량생산을 위해 8번 조건으로 탈지분말 투입량을 500g으로 늘려, 대량으로 효소처리한 경우도 탈지분말 대비 수율 18.19 %로 나타나 8번의 조건으로 캐비아 효소처리 분말 추출방법을 완성하였다.In addition, it can be seen that, after swelling for the purpose of tissue softening, the yield of the enzyme treatment was not higher than that before the swelling treatment. Although it was the highest, it was judged that
II. 항염증 및 피부실험 기능성 평가II. Anti-inflammatory and skin test functional evaluation
본 발명에서는 마우스 유래 대식세포인 RAW264.7을 사용하였고, 항원으로는 그람음성균의 세포벽 물질인 LPS를 사용하여 자극을 하였다. 캐비아 효소처리추출물의 경우 LPS로 자극된 대식세포에 농도별로 처리한 결과 염증성 싸이토카인인 IL-6, TNF-a를 억제시켜 항염증 효과를 보였다. 또한 인간 유래 섬유아세포인 Hs68에 UV를 조사한 결과 콜라겐분해효소인 MMP-1 감소와 탄성섬유 증가시켜서 피부 주름 및 탄력 개선에도 효과를 보인 것으로 나타났다.In the present invention, mouse-derived macrophages, RAW264.7, were used, and as an antigen, LPS, a cell wall material of Gram-negative bacteria, was used for stimulation. In the case of the caviar enzyme-treated extract, the LPS-stimulated macrophages were treated for each concentration, and as a result, the inflammatory cytokines IL-6 and TNF-a were inhibited, thereby showing an anti-inflammatory effect. In addition, as a result of UV irradiation on Hs68, a human-derived fibroblast, it was found that it was effective in improving skin wrinkles and elasticity by decreasing MMP-1, a collagen degrading enzyme, and increasing elastic fibers.
1. 항염증 실험1. Anti-inflammatory experiment
1.1 세포독성 결과1.1 Cytotoxicity Results
도 2는 RAW264.7 세포에서 캐비아 효소처리 분말 및 열수추출분말의 세포독성 결과 나타낸다. 캐비아 효소처리 분말 및 열수추출분말을 RAW264.7에 처리하여 (10, 50, 100, 250, 500 ppm) 24시간 배양한 뒤 MTT 용액을 5 mg/ml의 농도로 첨가하였다. 이후 DMSO로 용해시켜 450nm 파장으로 세포독성을 측정하였다. RAW264.7은 10% FBS, 1% P/S의 배지 조성에 37℃, 5% CO2 조건에서 배양하였다.2 shows the cytotoxicity results of caviar enzyme-treated powder and hot-water extract powder in RAW264.7 cells. Caviar enzyme-treated powder and hot water extract powder were treated with RAW264.7 (10, 50, 100, 250, 500 ppm) and cultured for 24 hours, and then MTT solution was added at a concentration of 5 mg/ml. After dissolution with DMSO, cytotoxicity was measured at a wavelength of 450 nm. RAW264.7 was cultured in a medium composition of 10% FBS and 1% P/S at 37° C., 5% CO 2 conditions.
도 1의 결과를 살펴보면 No enzyme군의 250, 500ppm을 제외하고 모든 조건 및 농도에서 세포독성 없는 것으로 나타났다. 즉, 세포독성이 없는 농도 내에서 기능성 효과를 보인다면 세포 사멸에 의한 지표 감소 또는 증가가 아닌 원료 효과 때문인 것을 확인할 수 있다.Looking at the results of Figure 1, it was found that there was no cytotoxicity in all conditions and concentrations except for 250 and 500 ppm of the No enzyme group. That is, if it shows a functional effect within a concentration without cytotoxicity, it can be confirmed that it is due to the raw material effect rather than the decrease or increase of the indicator due to apoptosis.
1.2. 사이토카인 IL-6 변화1.2. Cytokine IL-6 changes
도 3은 RAW264.7 세포에서 조건 별 열수추출분말 및 효소처리 분말의 IL-6 감소 효과를 나타낸다. RAW264.7에 캐비아 효소처리 분말 및 캐비아열수추출분말(10, 100 ppm)을 24시간 동안 처리한 후 최종 500 ng/ml 농도의 LPS를 처리하여 다시 24시간 배양하였다. 이후 상등액을 취하여 ELISA kit로 염증성 사이토카인인 IL-6를 정량하였다. RAW264.7은 10% FBS, 1% P/S의 배지 조성에 37℃, 5% CO2 조건에서 배양하였다.3 shows the IL-6 reduction effect of hot water extract powder and enzyme-treated powder for each condition in RAW264.7 cells. RAW264.7 was treated with caviar enzyme-treated powder and caviar hot water extract powder (10, 100 ppm) for 24 hours, and then treated with LPS at a final concentration of 500 ng/ml and cultured again for 24 hours. After taking the supernatant, the inflammatory cytokine IL-6 was quantified with an ELISA kit. RAW264.7 was cultured in a medium composition of 10% FBS and 1% P/S at 37° C., 5% CO 2 conditions.
도 3의 결과를 살펴보면 단일 및 복합 효소처리군 100ppm에서 IL-6 유의적 감소를 보였다. 캐비아 열수추출 및 효소미처리군은 대조군 (LPS처리군) 대비 염증성 사이토카인 IL-6 변화가 없었으나 효소처리군 3개군에서 IL-6의 유의적 감소를 보였다. 또한 각 효소 종류별 차이는 없었다. 이로부터 캐비아 탈지분말에 효소처리 시 항염증 효과를 보인 것으로 나타났다.Looking at the results of FIG. 3, IL-6 significantly decreased at 100 ppm of the single and complex enzyme treatment groups. The caviar hot water extraction and enzyme untreated group did not show any change in IL-6, an inflammatory cytokine, compared to the control group (LPS treated group), but showed a significant decrease in IL-6 in the three enzyme treatment groups. Also, there was no difference between each enzyme type. From this, it was found that the enzyme treatment of caviar skim powder showed an anti-inflammatory effect.
1.3. TNF-α 감소 효과1.3. TNF-α reducing effect
도 4는 RAW264.7 세포에서 조건 별 열수추출분말 및 효소처리 분말의 TNF-α 감소 효과를 나타낸다. RAW264.7에 캐비아 효소처리 분말 및 캐비아열수추출분말(10, 100 ppm)을 24시간 동안 처리한 후 최종 500 ng/ml 농도의 LPS를 처리하여 다시 24시간 배양하였다. 이후 상등액을 취하여 ELISA kit로 염증성 사이토카인인 TNF-α를 정량하였다. RAW264.7은 10% FBS, 1% P/S의 배지 조성에 37℃, 5% CO2 조건에서 배양하였다.4 shows the TNF-α reduction effect of hot water extract powder and enzyme-treated powder for each condition in RAW264.7 cells. RAW264.7 was treated with caviar enzyme-treated powder and caviar hot water extract powder (10, 100 ppm) for 24 hours, and then treated with LPS at a final concentration of 500 ng/ml and cultured again for 24 hours. After taking the supernatant, TNF-α, an inflammatory cytokine, was quantified with an ELISA kit. RAW264.7 was cultured in a medium composition of 10% FBS and 1% P/S at 37° C., 5% CO 2 conditions.
도 4의 결과를 살펴보면 단일 및 복합 효소처리군 100ppm에서 TNF-a 유의적 감소 결과를 보였다. 캐비아 열수추출물 및 효소미처리군에서 대조군 (LPS처리군) 대비 염증성 사이토카인인 TNF-α 변화가 없었으나 효소처리군 3개군에서 TNF-α의 유의적 감소를 보였다. 각 효소 종류 별 차이는 없었다. 이로부터 캐비아 탈지분말에 효소처리 시 항염증 효과를 보인 것으로 나타났다.Looking at the results in FIG. 4, TNF-a significantly decreased in 100 ppm of the single and complex enzyme treatment groups. There was no change in TNF-α, an inflammatory cytokine, in the caviar hot water extract and enzyme-untreated groups compared to the control group (LPS-treated group), but the enzyme-treated group showed a significant decrease in TNF-α in 3 groups. There was no difference between each enzyme type. From this, it was found that the enzyme treatment of caviar skim powder showed an anti-inflammatory effect.
2. 피부 기능성 개선 실험 결과2. Results of skin functional improvement test
2.1 MMP-1 발현 감소 효과2.1 Effect of reducing MMP-1 expression
도 5는 Hs68 세포에서 조건 별 열수추출분말 및 효소처리 분말의 MMP-1 발현 감소 효과를 나타낸다. 인간피부섬유아세포를 24시간 배양 후 20 mJ/cm2 의 UV를 조사 하고 다시 24시간 뒤 캐비아 효소처리 분말을 최종농도 10 ppm으로 처리하였다.Hs68 cell은 37℃, 5% CO2, 10% FBS, 1% P/S의 조성에서 배양하였고 샘플 처리 시에는 FBS를 제외한 조성에서 배양하였다. 실험군과 함께 배양된 Ps68 세포를 RNeasy kit를 이용하여 RNA 분리하여 Real time RT-PCR을 이용해 MMP-1의 mRNA 발현 변화를 확인하였다.5 shows the effect of reducing MMP-1 expression of hot water extract powder and enzyme-treated powder for each condition in Hs68 cells. After culturing human skin fibroblasts for 24 hours, they were irradiated with UV of 20 mJ/cm 2 , and 24 hours later, the caviar enzyme-treated powder was treated with a final concentration of 10 ppm. , and cultured in a composition of 1% P/S, and cultured in a composition excluding FBS when processing samples. RNA was isolated from Ps68 cells cultured with the experimental group using the RNeasy kit, and the change in MMP-1 mRNA expression was confirmed using real-time RT-PCR.
도 5의 결과를 살펴보면 Prozyme 및 혼합효소(Prozyme+Protamex) 처리군에서 UV처리군 대비 콜라겐분해 효소인 MMP-1이 감소하였으며, UV를 처리하지 않은 Control군과 비교하였을 때 유의적 차이가 없을 만큼 감소되었다. 이는 Prozyme군 및 혼합효소 처리군에서 콜라겐 분해효소 발현을 UV 처리 전 수준으로 감소시킬 수 있는 것을 나타낸다. 또한 열수추출물 및 효소미처리군보다 우수한 콜라겐 분해효소 저해 효과를 보였다.Looking at the results of Figure 5, the collagen-degrading enzyme MMP-1 was decreased in the Prozyme and mixed enzyme (Prozyme + Protamex) treatment group compared to the UV treatment group, and there was no significant difference compared to the Control group not treated with UV. decreased. This indicates that the collagen degrading enzyme expression can be reduced to the level before UV treatment in the Prozyme group and the mixed enzyme treatment group. In addition, it showed a superior collagen degrading enzyme inhibitory effect than the hot water extract and the enzyme-untreated group.
2.2 COL1A 증가 효과2.2 Effect of increasing COL1A
도 6은 Hs68세포에서 조건 별 열수추출 분말과 효소처리 분말의 COL1A 증가 효과를 나타낸다. 인간피부섬유아세포를 24시간 배양 후 캐비아 효소처리 분말을 최종농도 10 ppm으로 처리하여 24시간 추가 배양하였다. Hs68 cell은 37℃, 5% CO2, 10% FBS, 1% P/S의 조성에서 배양하였다. 실험군과 함께 배양된 Hs68 세포를 RNeasy kit로 RNA를 분리하여 Real time RT-PCR을 이용해 COL1A의 mRNA 발현 변화를 확인하였다.6 shows the effect of increasing COL1A of hot water extract powder and enzyme-treated powder for each condition in Hs68 cells. After culturing human skin fibroblasts for 24 hours, the caviar enzyme-treated powder was treated with a final concentration of 10 ppm and further cultured for 24 hours. Hs68 cells were cultured at 37°C, 5
도 6의 결과를 살펴보면 Protamex 및 혼합 효소처리군에서 EGCG군 수준 만큼은 아니나, COL1A 발현이 대조군 대비 유의적으로 증가하였다. 효소처리군 및 효소미처리군에서는 유의적인 차이를 보이지 않았다. 효소처리 시 효소 미처리 및 열수추출물보다 우수한 콜라겐 발현 증가 효과가 있었다.Looking at the results of FIG. 6 , COL1A expression was significantly increased in the Protamex and mixed enzyme treatment groups compared to the control group, although not as much as the EGCG group level. There was no significant difference between the enzyme-treated group and the enzyme-untreated group. In the case of enzyme treatment, there was an effect of increasing collagen expression which was superior to that of untreated and hot water extracts.
2.3 Fibrillin 발현 증가 효과2.3 Effect of Increasing Fibrillin Expression
도 7은 Hs68세포에서 조건 별 열수추출분말과 효소처리 분말의 Fibrillin 발현 증가 효과를 나타낸다. 인간피부섬유아세포(Ps68)를 24시간 배양 후 캐비아 효소처리 분말을 최종농도 10 ppm으로 처리하여 24시간 추가 배양하였다. Hs68 cell은 37℃, 5% CO2, 10% FBS, 1% P/S의 조성에서 배양하였다. 실험군과 함께 배양된 Hs68 세포를 RNeasy kit로 RNA를 분리하여 Real time RT-PCR을 이용해 Fibrillin의 mRNA 발현 변화를 확인하였다.7 shows the effect of increasing the fibrillin expression of hot water extract powder and enzyme-treated powder for each condition in Hs68 cells. After culturing human skin fibroblasts (Ps68) for 24 hours, the caviar enzyme-treated powder was treated with a final concentration of 10 ppm and further cultured for 24 hours. Hs68 cells were cultured at 37°C, 5
도 7의 결과를 살펴보면 효소 미처리군 및 혼합 효소처리군에서 CTRL군 대비 Fibrillin의 발현량이 유의적으로 증가 하였고, EGCG와 유사한 수치로 증가하였다. 효소처리군 중에서는 단독 효소처리는 유의적 차이를 보이지 않았고 혼합 효소처리군에서만 유의적 차이를 보였다. 열수추출물, 효소 단독처리군보다 우수한 Fibrillin 발현 증가 효과가 있어 피부 탄력이 증가하여 주름이 개선되는 효과를 보인다.Looking at the results of FIG. 7 , the expression level of Fibrillin was significantly increased in the enzyme-untreated group and the mixed enzyme-treated group compared to the CTRL group, and increased to a value similar to that of EGCG. Among the enzyme-treated groups, the single enzyme treatment did not show a significant difference, and only the mixed enzyme treatment group showed a significant difference. It has an effect of increasing fibrillin expression that is superior to that of the hot water extract and enzyme-only treatment group, so skin elasticity is increased and wrinkles are improved.
이상의 실험을 통하여 캐비아 효소처리 분말이 항염증 및 피부 개선에 도움이 될 수 있는 원료임을 확인하였다. 또한 캐비아 효소처리 분말이 효소처리되지 않은 추출물보다 우수한 활성이 확인되었다.Through the above experiments, it was confirmed that the caviar enzyme-treated powder is a raw material that can help anti-inflammatory and skin improvement. In addition, it was confirmed that the caviar enzyme-treated powder had superior activity than the unenzymatically-treated extract.
도 8은 본 발명으로부터 완성된 캐비아 효소처리 분말 조성물을 나타낸다. 본 발명으로부터 제조된 캐비아 효소처리 분말 추출물을 이용하여 항염증 및 피부 개선용 건강기능식품으로 제조할 수 있다. 건강 기능식품은 캐비아 효소처리 분말 추출물이 0.01 내지 99.9중량%로 포함되도록 산제, 과립제, 정제, 캡슐제, 연질캡슐제, 과립제, 액제 중에서 선택되는 어느 하나의 형태로 제형화하여 제조한다.8 shows the caviar enzyme-treated powder composition completed from the present invention. By using the caviar enzyme-treated powder extract prepared from the present invention, it can be prepared as a health functional food for anti-inflammatory and skin improvement. Health functional food is prepared by formulating in any one form selected from powders, granules, tablets, capsules, soft capsules, granules, and liquids so that the caviar enzyme-treated powder extract is contained in an amount of 0.01 to 99.9% by weight.
본 발명의 캐비아 효소처리 분말 추출물을 유효성분으로 포함하는 항염증 및 피부 개선용 조성물은 독성 및 부작용 없이 안전하게 사용될 수 있는 항염증 및 피부 개선용 기능성 식품 등으로 이용될 수 있으므로 산업상 이용가능성이 있다.The composition for anti-inflammatory and skin improvement comprising the caviar enzyme-treated powder extract of the present invention as an active ingredient has industrial applicability because it can be used as an anti-inflammatory and skin-improving functional food that can be safely used without toxicity and side effects. .
Claims (4)
It contains a caviar enzyme-treated powder extract as an active ingredient, and the caviar enzyme-treated powder extract is an extract available from the supercritical extraction method, and the supercritical extraction pressure is 400 bar, temperature 40° C., flow rate 60 ml/min, extraction time 300 minutes. Functional composition for anti-inflammatory and skin improvement, characterized in that it consists of
A functional composition for anti-inflammatory and skin improvement comprising caviar enzyme-treated powder extract as an active ingredient, wherein the caviar enzyme-treated powder extract is obtained by primary enzyme treatment with Prozyme 1000L and secondary enzyme treatment with Protamex
캐비아 탈지분말에, 10배수의 증류수를 첨가한 후, 효소처리를 실시하는 단계 및;
캐비아 효소처리액을 여과후 여과액을 15brix까지 농축하여 동결건조하는 단계로 제조되는 것을 특징으로 하는 항염증 및 피부 개선용 기능성 조성물 제조방법Freeze-drying the raw caviar; supercritically extracting caviar freeze-dried powder to obtain caviar skim powder;
After adding 10 times distilled water to the caviar skim powder, performing an enzyme treatment;
Method for producing a functional composition for anti-inflammatory and skin improvement, characterized in that it is prepared by filtration of the caviar enzyme treatment solution and then freeze-drying the filtrate by concentrating the filtrate to 15brix
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210092608A KR102362960B1 (en) | 2021-07-15 | 2021-07-15 | Functional composition for anti-inflammatory and skin improvement comprising caviar enzyme-treated powder extract as an active ingredient. |
PCT/KR2022/001520 WO2023286964A1 (en) | 2021-07-15 | 2022-01-27 | Functional composition for anti-inflammatory and skin improvement, comprising caviar enzyme-treated powder extract as active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210092608A KR102362960B1 (en) | 2021-07-15 | 2021-07-15 | Functional composition for anti-inflammatory and skin improvement comprising caviar enzyme-treated powder extract as an active ingredient. |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102362960B1 true KR102362960B1 (en) | 2022-02-25 |
Family
ID=80490410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210092608A KR102362960B1 (en) | 2021-07-15 | 2021-07-15 | Functional composition for anti-inflammatory and skin improvement comprising caviar enzyme-treated powder extract as an active ingredient. |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102362960B1 (en) |
WO (1) | WO2023286964A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008127328A (en) * | 2006-11-21 | 2008-06-05 | Atena:Kk | Cosmetic product and extract included therein |
KR20120018841A (en) * | 2010-08-24 | 2012-03-06 | 세종대학교산학협력단 | Preparing method of hypoallergenic rice protein extract and hypoallergenic rice protein extract by the same |
KR20130088997A (en) | 2012-02-01 | 2013-08-09 | 주식회사 유로코스텍 | Cosmetic composition for hair growth and restoration from caviar extracts and its fermentation |
KR20130089137A (en) * | 2012-02-01 | 2013-08-09 | 주식회사 유로코스텍 | Fermented caviar extract and its cosmetic usage |
KR20190090703A (en) | 2018-01-25 | 2019-08-02 | 스킨엘릭스(주) | The Manufacturing process of emulsion containing Caviar and Composition Thereof |
KR20200108616A (en) | 2019-03-11 | 2020-09-21 | 엔오스 주식회사 | Cosmetic composition containing caviar extracts and cosmetic manufacturing method using therof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101517950B1 (en) * | 2014-05-30 | 2015-05-06 | 주식회사 코씨드바이오팜 | Cosmetic composition with mucus from sturgeon |
-
2021
- 2021-07-15 KR KR1020210092608A patent/KR102362960B1/en active IP Right Grant
-
2022
- 2022-01-27 WO PCT/KR2022/001520 patent/WO2023286964A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008127328A (en) * | 2006-11-21 | 2008-06-05 | Atena:Kk | Cosmetic product and extract included therein |
KR20120018841A (en) * | 2010-08-24 | 2012-03-06 | 세종대학교산학협력단 | Preparing method of hypoallergenic rice protein extract and hypoallergenic rice protein extract by the same |
KR20130088997A (en) | 2012-02-01 | 2013-08-09 | 주식회사 유로코스텍 | Cosmetic composition for hair growth and restoration from caviar extracts and its fermentation |
KR20130089137A (en) * | 2012-02-01 | 2013-08-09 | 주식회사 유로코스텍 | Fermented caviar extract and its cosmetic usage |
KR20190090703A (en) | 2018-01-25 | 2019-08-02 | 스킨엘릭스(주) | The Manufacturing process of emulsion containing Caviar and Composition Thereof |
KR20200108616A (en) | 2019-03-11 | 2020-09-21 | 엔오스 주식회사 | Cosmetic composition containing caviar extracts and cosmetic manufacturing method using therof |
Also Published As
Publication number | Publication date |
---|---|
WO2023286964A1 (en) | 2023-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9394513B2 (en) | Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant | |
TWI516280B (en) | Use of chenopodium formosanum extract for manufacture of composition for enhancing secretion of collagen and preventing cutaneous aging | |
JP5270680B2 (en) | Soybean fermented polymer substance mixed with folic acid and composition containing the same | |
KR20190014477A (en) | Tremella fuciformis extraxt, preparation method thereof and Use the same | |
JPWO2006075558A1 (en) | Egg-derived bone strengthening composition | |
KR102403309B1 (en) | Natural mixture for improving health and functional cosmetic agent including the same for preventing hair loss | |
CN104323228A (en) | Method for producing pleurotus eryngii flavour liquid | |
JP6301522B1 (en) | Antihypertensive composition and method for producing the same | |
KR102362960B1 (en) | Functional composition for anti-inflammatory and skin improvement comprising caviar enzyme-treated powder extract as an active ingredient. | |
KR102529075B1 (en) | Composition for preventing hair loss and improving scalp containing exosomes | |
KR102016640B1 (en) | Composition containing extract using process of herbal medicine | |
KR20190071017A (en) | Manufacturing method of Health Food using honeybee pollen | |
KR20090029528A (en) | Manufacturing method of health assistance food using ginseng steamed red and silk peptide and its health assistance food | |
KR102355751B1 (en) | Pentosidine production inhibitor | |
KR20150000110A (en) | A composition for the treatment or prevention of asthma comprising alginate | |
JP5684989B2 (en) | Enzyme-treated and gonococcal fermentation-treated product | |
JP6209580B2 (en) | Ultraviolet ray obstruction reducing agent, method for producing ultraviolet ray obstruction reducing agent, medium additive, microorganism diluent additive, medium, microorganism diluent, external preparation and cosmetics | |
KR101750619B1 (en) | Preparation method of osmotic enzyme fermentation product using momordica charantia and houttuynia cordata, the fermentation product prepared thereby and cosmetic, food or pharmaceutical composition comprising the same | |
KR101713115B1 (en) | Cosmetic composition containing the fermented extract of allium monanthum, allium scorodorpasum, allium tuberosum, allium fistulosum and scilla scilloides | |
CN116963614A (en) | Preparation method of fermented cornu Cervi Pantotrichum extract processed by three steps | |
KR20220099176A (en) | A composition with anti-inflammation activity and skin elasticity improvement efficacy comprising mixed ferment extracts of natural products | |
KR100987517B1 (en) | Biopolymer produced by fermenting the extract of soybean with folic acid and a composition containing thereof | |
KR20140148276A (en) | Manufacturing method of allergen removed water soluble royal jelly and use thereof | |
JP2019136027A (en) | Fermentation product | |
KR102510870B1 (en) | Composition for promoting hair growth containing peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |